索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王俊俊 陆伦根 蔡晓波.脂肪因子在非酒精性脂肪性肝病中的作用[J].国际消化病杂志,2019,03:149-152,215.
点击复制

脂肪因子在非酒精性脂肪性肝病中的作用(PDF)

《国际消化病杂志》[ISSN:1673-534X/CN:31-1953/R]

期数:
2019年03期
页码:
149-152,215
栏目:
出版日期:
2019-06-25

文章信息/Info

Title:
-
作者:
王俊俊 陆伦根 蔡晓波
200080 上海交通大学附属第一人民医院消化科
Author(s):
-
关键词:
脂肪因子;  非酒精性脂肪性肝病;  肝纤维化
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-534X.2019.03.002
文献标识码:
-
摘要:
非酒精性脂肪性肝病(NAFLD)是一种慢性进行性肝病,其发病与肥胖、2型糖尿病密切相关。脂肪组织能产生和分泌具有促炎和抗炎特性的细胞因子,在NAFLD发病过程中起着至关重要的作用。脂联素和瘦素在NAFLD的病理生理学方面具有明确的作用,其他脂肪因子如抵抗素、内脂素、趋化素、视黄醇结合蛋白4、丝氨酸蛋白酶抑制剂、Apelin等在NAFLD发病机制和进展中的作用需要进一步研究。此外,用于治疗NAFLD的药物如噻唑烷二酮类、他汀类药物等对脂肪因子水平产生有利影响,可能有助于改善肝功能。该文对脂肪因子与NAFLD之间的关系作一综述,并讨论脂肪因子作为NAFLD潜在治疗靶点的意义。
Abstract:
-

参考文献/References

1 Adolph TE, Grander C, Grabherr F, et al. Adipokines and Non-Alcoholic fatty liver disease: multiple interactions[J]. Int J Mol Sci, 2017, 18(8). pii:E1649.
2 Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review[J]. Metabolism, 2015, 64(1): 60-78.
3 Polyzos SA, Aronis KN, Kountouras J, et al. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Diabetologia, 2016, 59(1): 30-43.
4 Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years[J]. Gut, 2010, 59(7): 969-974.
5 Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up[J]. J Hepatol, 2012, 56(5): 1145-1151.
6 Mantzoros CS, Moschos S, Avramopoulos I, et al. Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans[J]. J Clin Endocrinol Metab, 1997, 82(10): 3408-3413.
7 Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment[J]. J Hepatol, 2013, 59(1): 131-137.
8 Yamauchi T, Iwabu M, Okada-Iwabu M, et al. Adiponectin receptors: a review of their structure, function and how they work[J]. Best Pract Res Clin Endocrinol Metab, 2014, 28(1): 15-23.
9 Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis[J]. Trends Endocrinol Metab, 2015, 26(3): 153-161.
10 Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Metabolism, 2011, 60(3): 313-326.
11 Zhang H, Niu Y, Gu H, et al. Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease[J]. J Clin Lab Anal, 2019, 33(3): e22709.
12 Polyzos SA, Kountouras J, Zavos C, et al. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease[J]. Diabetes Obes Metab, 2010, 12(5): 365-383.
13 SenateE, Colak Y, Yesil A, et al. Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and nonalcoholic steatohepatitis scores[J]. Minerva Med, 2012, 103(5): 369-376.
14 Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis(NASH)[J]. Obes Surg, 2008, 18(11): 1430-1437.
15 Fitzpatrick E, Dew TK, Quaglia A, et al. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease[J]. Pediatr Obes, 2012, 7(6): 471-479.
16 Musso G, Bo S, Cassader M, et al. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism[J]. Am J Clin Nutr, 2013, 98(4): 895-906.
17 Shen C, Zhao CY, Wang W, et al. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis[J]. BMC Gastroenterol, 2014, 14: 39.
18 Qiu Y, Wang SF, Yu C, et al. Association of circulating adipsin, visfatin, and adiponectin with nonalcoholic fatty liver disease in adults: a Case-Control study[J]. Ann Nutr Metab, 2019, 74(1): 44-52.
19 Kukla M, Ciupińska-Kajor M, Kajor M, et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery[J]. Pol J Pathol, 2010, 61(3): 147-153.
20 Genc H, Dogru T, Kara M, et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease[J]. Ann Hepatol, 2013, 12(4): 548-555.
21 Liang N, Chen Y, Yang L, et al. Visfatin increases miR-21 to promote migration in HCC[J]. Cell Mol Biol(Noisy-le-grand), 2018, 64(6): 48-52.
22 Krautbauer S, Wanninger J, Eisinger K, et al. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver[J]. Exp Mol Pathol, 2013, 95(2): 199-205.
23 Kukla M, Zwirska-Korczala K, Hartleb M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease[J]. Scand J Gastroenterol, 2010, 45(2): 235-242.
24 Polyzos SA, Kountouras J, Anastasilakis AD, et al. Irisin in patients with nonalcoholic fatty liver disease[J]. Metabolism, 2014, 63(2): 207-217.
25 Pohl R, Haberl EM, Rein-Fischboeck L, et al. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis[J]. Eur J Clin Invest, 2017, 47(1): 7-18.
26 D?cke S, Lock JF, Birkenfeld AL, et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease[J]. Eur J Endocrinol, 2013, 169(5): 547-557.
27 Liu Y, Mu D, Chen H, et al. Retinol-Binding protein 4 induces hepatic mitochondrial dysfunction and promotes hepatic steatosis[J]. J Clin Endocrinol Metab, 2016, 101(11): 4338-4348.
28 Chen XE, Shen TR, Li Q, et al. Retinol binding protein-4 levels and non-alcoholic fatty liver disease: a community-based cross-sectional study[J]. Sci Rep, 2017, 7: 45100.
29 Schina M, Koskinas J, Tiniakos D, et al. Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease[J]. Hepatol Res, 2009, 39(10): 972-978.
30 Cengiz C, Ardicoglu Y, Bulut S, et al. Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis?[J]. Eur J Gastroenterol Hepatol, 2010, 22(7): 813-819.
31 Alkhouri N, Lopez R, Berk M, et al. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease[J]. J Clin Gastroenterol, 2009, 43(10): 985-989.
32 Kashyap SR, Diab DL, Baker AR, et al. Triglyceride levels and not adypokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort[J]. Obesity(Silver Spring), 2009, 17(9): 1696-1701.
33 Yang W, Li Y, Tian T, et al. Serum vaspin concentration in elderly type 2 diabetes mellitus patients with differing body mass index: a Cross-Sectional study[J]. Biomed Res Int, 2017: 4875026.
34 Waluga M, Kukla M, ?orniak M, et al. Vaspin mRNA levels in the liver of morbidly obese women with nonalcoholic fatty liver disease[J]. Pol J Pathol, 2017, 68(2): 128-137.
35 Aktas B, Yilmaz Y, Eren F, et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease[J]. Metabolism, 2011, 60(4): 544-549.
36 Daviaud D, Boucher J, Gesta S, et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue[J]. FASEB J, 2006, 20(9): 1528-1530.
37 Principe A, Melgar-Lesmes P, Fernández-Varo G, et al. The hepatic apelin system: a new therapeutic target for liver disease[J]. Hepatology, 2008, 48(4): 1193-1201.
38 Montazerifar F, Bakhshipour AR, Karajibani M, et al. Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease[J]. J Res Med Sci, 2017, 22: 70.
39 Ercin CN, Dogru T, Tapan S, et al. Plasma apelin levels in subjects with nonalcoholic fatty liver disease[J]. Metabolism, 2010, 59(7): 977-981.

备注/Memo

备注/Memo:
作者单位: 200080 上海交通大学附属第一人民医院消化科
通信作者: 蔡晓波,Email: caixiaobo1979@hotmail.com
更新日期/Last Update: 2019-06-25